Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial And Canadian Pacific

Published 05/17/2017, 09:30 PM
Updated 07/09/2023, 06:31 AM

For Immediate Release

Chicago, IL – May 18, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (NYSE:PFE) (NYSE: PFE Free Report ), Home Depot (NYSE:HD) (NYSE: HD Free Report ), ConocoPhillips (NYSE:COP) (NYSE: COP Free Report ), Prudential Financial (NYSE:PRU) (NYSE: PRU Free Report ) and Canadian Pacific (NYSE: CP Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Wednesday’s Analyst Blog:

Stock Market Rattled Wednesday & New Research Reports

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (NYSE: PFE Free Report ), Home Depot (NYSE:HD Free Report ) and ConocoPhillips (NYSE: COP Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>

A brief comment about today’s market action is in order before we discuss the featured analyst reports. Stocks appeared immune to the Washington drama for a while, but have started taking note of the issue in today’s issue. This isn’t helping stocks or the dollar, though safe-haven trades into treasuries and gold are doing better. The key question that market participants are grappling with is the future of the Trump Agenda in the current backdrop of a never-ending cycle of crises. If the administration is unable to lead Congress into enacting tax reforms and other pro-growth measures, then we probably need to get ready for the market to retrace its steps to the pre-election level.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

As a reference, the S&P 500 index is up +12% in the post-election period while the Russell 2000 index is up +15.7%.

Today’s Featured Stock Research Reports

Pfizer shares have underperformed the peer group as well as the broader market over the past year (the stock is down -1.7% over the last one year vs. a +4.6% increase for the Zacks Large-Cap Pharma industry) +15.8% gain for the S&P 500 index) on continued drug pricing uncertainty that have refused to go away even after the election. These headwinds notwithstanding, the Zacks analyst is pointing out that Pfizer is strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. Also, cost-savings and share buybacks should help Pfizer achieve its earnings guidance. While the Hospira acquisition has significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal has strengthened its cancer franchise by adding Xtandi to its portfolio. (You can read the full research report on Pfizer here >>> )

Home Depot sharesare up +16.3% in the year-to-date period, outperforming the Zacks Retail sector (up +13.2%) and the broader market (S&P 500 up +7.5%) in that same time period. Improving customer experience, solid execution and consistent housing market recovery helped the company post an earnings surprise in first-quarter fiscal 2017, retaining the four-year long trend of beating earnings estimates. The company’s relentless focus on offering innovative products, boosting interconnected customer experience and driving productivity seems to be paying off. Moreover, the company raised earnings guidance for fiscal 2017 while retaining its sales view. On the flip side, market participants can justifiably raise valuation concerns, particularly following the stock’s stellar recent performance. (You can read the full research report on Home Depot here >>> )

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

ConocoPhillips shares are down -5.9% in the year-to-date period, roughly in-line with the Zacks Energy sector’s performance in the same time period, on weakness in oil prices. During the first quarter of this year, the company’s loss per share narrowed considerably while its top line beat estimates. This was owing to improved commodity price realizations and increased production. But the quarterly loss compared unfavorably with estimates for the January–March quarter. Higher expenses, along with normal field declines and dispositions, led to the underperformance. However, the company's plan to reposition its asset base by divesting low-margin assets and using the sale proceeds to pay down debt and return cash to shareholders is proceeding nicely. The company decided to divest its interest in the San Juan Basin – rich in natural gas – for a consideration of almost $3 billion. The accord reflects ConocoPhillips’ intention to lower its exposure to the U.S. natural gas business, which has been less profitable in recent years. (You can read the full research report on ConocoPhillips here >>> )

Other noteworthy reports we are featuring today include Prudential (LON:PRU) Financial (NYSE:PRU Free Report ) and Canadian Pacific (NYSE: CP Free Report ).

The Best & Worst of Zacks

Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 11X worse than the market. See these critical buys and sells free >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on HY - FREE

Get the full Report on AIT - FREE

Get the full Report on UFI - FREE

Get the full Report on HSC - FREE

Get the full Report on NNBR - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



Pfizer, Inc. (PFE): Free Stock Analysis Report

Home Depot, Inc. (The) (HD): Free Stock Analysis Report

ConocoPhillips (COP): Free Stock Analysis Report

Prudential Financial, Inc. (PRU): Free Stock Analysis Report

Canadian Pacific Railway Limited (CP): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.